Creates provisions relating to ibogaine treatment

This bill creates a grant program to fund FDA-approved clinical trials using ibogaine (a substance under review for treating opioid use disorder and mental health conditions). It requires state-based medical entities with specific research expertise, matching non-state funds, and partnerships with other states to apply for grants. The bill establishes two dedicated funds: one for grant disbursements and another to manage revenue from intellectual property rights generated by successful trials, with funds directed toward veterans and at-risk populations. It mandates quarterly reporting on trial progress and financials to the health department, while requiring physician supervision for ibogaine administration during trials.